Manisha Bhutani

9PUBLICATIONS
66CO-AUTHORS
Medical infection agents (incl. prions)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Sep 18, 2026
Toward more accurate adverse event attribution in multiple myeloma clinical trials.

|Sep 02, 2026
Teclistamab and Daratumumab Immune-Based Doublet Therapy for Relapsed/Refractory Multiple Myeloma: the TRIMM-2 Study.

|May 12, 2026
Daratumumab-bortezomib-cyclophosphamide-dexamethasone for newly diagnosed amyloidosis: ANDROMEDA final survival analysis.

|Feb 20, 2026
Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma.

Shebli Atrash, James Symanowski, Myra Robinson

|Sep 22, 2025
Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study.

Ajai Chari, Niels W C J van de Donk, Bhagirathbhai Dholaria

|Aug 01, 2025
Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy.

Binod Dhakal, Othman S Akhtar, David Fandrei

Pageof 2

Frequent Collaborators

3 joint publications

Shebli Atrash

3 joint publications

Reed Friend

3 joint publications

Peter Voorhees

2 joint publications

Paula Rodriguez-Otero